EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Spatial Cancer-Immune Phenotypes Predict Shorter Recurrence-Free Survival in the No Specific Molecular Profile Molecular Subtype of Endometrial Carcinoma

Dario de Biase, Jacopo Lenzi, Claudio Ceccarelli, Thais Maloberti, Marco Grillini, Camelia Alexandra Coadǎ, Claudio Zamagni, Pierandrea De Iaco, Anna Myriam Perrone, Donatella Santini, Martin Köbel, Cheng-Han Lee und 2 weitere

Modern Pathology · 2025-01 · 38 (1) · 100624

DOI: 10.1016/j.modpat.2024.100624 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2025-01. Verfasst von Dario de Biase und 13 weiteren Autor:innen. Beteiligte Einrichtung: Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Pharmacy and Biotechnol…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Fondazione AIRC per la ricerca sul cancro ETS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Compartmentation of the immune response into 3 main spatial cancer-immune phenotypes (SCIs) - inflamed, excluded, and desert - has been proposed as the main predictor of response to immune checkpoint inhibitors in solid tumors. The objective of the study was to define and characterize the SCI in a consecutive series of 213 endometrial carcinomas (ECs) by correlating it with molecular subtypes, clinicopathologic features, and prognosis. Immunohistochemistry (IHC) and next-generation sequencing were used to assign surrogate molecular EC subtypes: POLE mutant (POLE), mismatch repair deficient (MMRd), TP53 mutant (p53abn), and no specific molecular profile (NSMP). Immune cell markers (CD20, CD3, CD8, CD68, PD-L1) were assessed by IHC on whole sections and quantified by digital image analysis to define the 3 SCIs. ECs were stratified into 4 molecular subtypes: 17 (8.0%) POLE, 68 (31.9%) MMRd, 42 (19.7%) p53abn, and 86 (40.4%) NSMP. SCI determination showed 105 (49.3%) inflamed, 62 (29.1%) desert, and 46 (25.6%) excluded tumors. The inflamed phenotype was more prevalent in MMRd (64.7%) and POLE (76.5%) subtypes compared with NSMP (45.3%) and p53abn (21.4%). SCI revealed a strong correlation with disease-free survival in NSMP tumors: inflamed 96.2%, desert 83.2%, and excluded 40.5%. The SCI prognostic impact was also maintained in NSMP cases treated with adjuvant therapy resulting in a significant difference in recurrence between the inflamed and excluded phenotypes. To simplify SCI determination, a subset of immune cell markers was selected as appropriate to define the 3 SCI patterns: high intraepithelial CD8 for the inflamed phenotype; CD68, CD20, and PD-L1 to discriminate between desert and excluded tumors. The integration of SCI into molecular classification could be a promising opportunity to improve the prognostic risk stratification of patients and may guide the therapeutic approach, particularly in the NSMP subtype. Thus, the different patterns of immune response are a new prognostic parameter in the NSMP subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsBiomarkers, TumorHumansFemaleMiddle AgedAgedPhenotypeTumor MicroenvironmentAdultAged, 80 and overDisease-Free SurvivalMutationPrognosisImmunohistochemistry

Stichwörter der Autor:innen

endometrial carcinomaimmune responsemolecular classificationprognosisspatial-cancer immune phenotypetumor microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Pharmacy and Biotechnology (FaBit), University of Bologna, Bologna, Italy.
  • Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Morpho-functional Sciences, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • Fondazione AIRC per la ricerca sul cancro ETS

Zitieren

APA

de Biase, D., Lenzi, J., Ceccarelli, C., Maloberti, T., Grillini, M., Coadǎ, C. A., Zamagni, C., De Iaco, P., Perrone, A. M., Santini, D., Köbel, M., Lee, C. H., Tallini, G., & De Leo, A. (2025). Spatial Cancer-Immune Phenotypes Predict Shorter Recurrence-Free Survival in the No Specific Molecular Profile Molecular Subtype of Endometrial Carcinoma. Modern Pathology, 38(1), 100624. https://doi.org/10.1016/j.modpat.2024.100624

Vancouver

de Biase D, Lenzi J, Ceccarelli C, Maloberti T, Grillini M, Coadǎ CA, et al. Spatial Cancer-Immune Phenotypes Predict Shorter Recurrence-Free Survival in the No Specific Molecular Profile Molecular Subtype of Endometrial Carcinoma. Modern Pathology. 2025;38(1):100624. doi:10.1016/j.modpat.2024.100624

BibTeX
@article{deBiase2025,
  author = {de Biase, Dario and Lenzi, Jacopo and Ceccarelli, Claudio and Maloberti, Thais and Grillini, Marco and Coadǎ, Camelia Alexandra and Zamagni, Claudio and De Iaco, Pierandrea and Perrone, Anna Myriam and Santini, Donatella and Köbel, Martin and Lee, Cheng-Han and Tallini, Giovanni and De Leo, Antonio},
  title = {Spatial Cancer-Immune Phenotypes Predict Shorter Recurrence-Free Survival in the No Specific Molecular Profile Molecular Subtype of Endometrial Carcinoma},
  journal = {Modern Pathology},
  year = {2025},
  volume = {38},
  number = {1},
  pages = {100624},
  doi = {10.1016/j.modpat.2024.100624}
}
Kostenlos starten →